Insulin Resistance and Adenomas of the Colorectum
胰岛素抵抗和结直肠腺瘤
基本信息
- 批准号:6606910
- 负责人:
- 金额:$ 36.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-07-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:adenoma apoptosis binding proteins biomarker body physical activity cancer risk cell proliferation clinical research colorectal neoplasms dietary lipid endoscopy gastrointestinal imaging /visualization gene mutation glucose tolerance hormone regulation /control mechanism human subject hypertriglyceridemia insulin insulin sensitivity /resistance insulinlike growth factor intestinal mucosa neoplasm /cancer epidemiology neoplasm /cancer genetics obesity oncogenes
项目摘要
There is considerable evidence that insulin and/or insulin-like
growth factors (IGFs) can increase risk of colorectal neoplasia. Epidemiologic
risk factors for colorectal neoplasia are similar to those for insulin
resistance syndromes, and prospective studies have shown both diabetes and
higher levels of IGF-1 to be associated with colorectal cancer risk. No
previous studies have included direct measures of insulin resistance, nor have
any included complete ascertainment of colorectal neoplasia by direct
examination of the entire colorectum. This study will assess the relationship
between insulin resistance and colorectal neoplasia by taking advantage of a
unique opportunity to examine a multi-ethnic cohort on whom prior measures of
insulin sensitivity have been made. The Insulin Resistance and Atherosclerosis
Study (IRAS) is a cohort study supported by the National Heart Lung and Blood
Institute. IRAS examined 1628 people of average age 55 in 1991-1994 for
atherosclerosis risk factors. The cohort, assembled in four clinical centers
(Alamosa, Co., Los Angeles, Oakland, and San Antonio) was established to be
multi-ethnic (34 percent Hispanic, 28 percent African American, and 38 percent
non-Hispanic white), bi-gender, and varied in diabetes risk. In 1998-1 999 over
85 percent of the surviving cohort was re-examined. Both of the examinations
have included measures of self-reported risk factors for atherosclerosis (diet,
physical activity, tobacco use, family history) as well as anthropometry and,
most importantly, oral glucose tolerance testing and frequently-sampled
intravenous glucose tolerance tests (FSIGT). The FSIGT is a sensitive and
specific measure of insulin resistance. All surviving cohort members (estimated
1518) will be invited to have a screening colonoscopy. Feasibility data
indicate that 1000 will agree to have a colonoscopic exam, among whom we
estimate 240 (range 206-274) will have adenomas. Mucosal biopsies will be taken
from the cecum and rectum of all subjects, and all adenomas will be removed and
examined for histologic features, Ki-ras mutations, proliferation, and
apoptosis. Serum samples will be assayed for insulin, IGF-1, IGFBPI, and IGFBP3
levels for all cohort members at both the time of colonoscopy, as well as at
the time of two earlier examinations (199 1-4 and 1998-9) using stored serum
samples. This study offers the advantage of the availability of prospective
measures of glucose tolerance, insulin resistance, measurements of most
colorectal neoplasia risk factors, and the availability of stored blood samples
from a multi-ethnic and bi-gender cohort. Complete colorectal visualization of
this entire cohort will enable unbiased estimates of colorectal neoplasia risk
related to these factors. This study therefore offers a time-efficient and a
cost-efficient method to test the hypothesis that colorectal neoplasia risk is
increased substantially by factors related to insulin resistance, and to
examine the biologic mechanisms whereby that risk is increased.
有大量证据表明胰岛素和/或胰岛素样药物
生长因子(IGF)会增加结直肠肿瘤的风险。流行病学
结直肠肿瘤的危险因素与胰岛素相似
抵抗综合症,前瞻性研究表明糖尿病和
较高水平的 IGF-1 与结直肠癌风险相关。不
之前的研究已经包括了胰岛素抵抗的直接测量,也没有
任何包括通过直接完全确定结直肠肿瘤
检查整个结直肠。这项研究将评估这种关系
通过利用胰岛素抵抗和结直肠肿瘤之间的优势
独特的机会来检查多种族群体,对他们进行先前的测量
已做出胰岛素敏感性。胰岛素抵抗和动脉粥样硬化
研究 (IRAS) 是一项由国家心肺血液中心支持的队列研究
研究所。 IRAS 在 1991 年至 1994 年间对 1628 名平均年龄 55 岁的人进行了检查
动脉粥样硬化的危险因素。该队列聚集在四个临床中心
(阿拉莫萨县、洛杉矶、奥克兰和圣安东尼奥)成立
多种族(34% 为西班牙裔,28% 为非洲裔美国人,38% 为
非西班牙裔白人)、双性别,并且糖尿病风险各不相同。 1998-1999年结束
85% 的幸存队列接受了重新检查。两次考试
包括自我报告的动脉粥样硬化危险因素的测量(饮食、
体力活动、吸烟、家族史)以及人体测量学,
最重要的是,口服葡萄糖耐量测试和频繁采样
静脉内葡萄糖耐量试验(FSIGT)。 FSIGT 是一个敏感且
胰岛素抵抗的具体测量。所有幸存的队列成员(估计
1518)将被邀请进行结肠镜检查筛查。可行性数据
表明有 1000 人同意进行结肠镜检查,其中我们
估计 240 人(范围 206-274)将患有腺瘤。将进行粘膜活检
所有受试者的盲肠和直肠中的所有腺瘤都将被切除并
检查组织学特征、Ki-ras 突变、增殖和
细胞凋亡。将检测血清样本中的胰岛素、IGF-1、IGFBPI 和 IGFBP3
所有队列成员在结肠镜检查时以及在
使用储存血清进行的两次早期检查(199 1-4 和 1998-9)的时间
样品。这项研究的优点是可以获得前瞻性的
葡萄糖耐量、胰岛素抵抗的测量,大多数的测量
结直肠肿瘤危险因素以及储存血样的可用性
来自多种族和双性别群体。完整的结直肠可视化
整个队列将能够公正地估计结直肠肿瘤风险
与这些因素有关。因此,本研究提供了一种省时且有效的方法
检验结直肠肿瘤风险为假设的经济有效的方法
与胰岛素抵抗相关的因素显着增加,并且
检查该风险增加的生物学机制。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.
- DOI:10.1186/s12885-015-1115-2
- 发表时间:2015-03-14
- 期刊:
- 影响因子:3.8
- 作者:Henry CJ;Sedjo RL;Rozhok A;Salstrom J;Ahnen D;Levin TR;D'Agostino R Jr;Haffner S;DeGregori J;Byers T
- 通讯作者:Byers T
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ralph B. DAgostino其他文献
Ralph B. DAgostino的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ralph B. DAgostino', 18)}}的其他基金
Sub-component for Institution # 16-01848 Biostatistics
机构的子组件
- 批准号:
10220886 - 财政年份:2017
- 资助金额:
$ 36.83万 - 项目类别:
Limited Competition for the Continuation of the SEARCH for Diabetes in Youth Cohort Study (UC4)SEARCH for Diabetes in Youth Cohort Study
继续进行青少年糖尿病研究 (UC4) 青少年糖尿病研究的有限竞争
- 批准号:
9343335 - 财政年份:2015
- 资助金额:
$ 36.83万 - 项目类别:
Insulin Resistance and Adenomas of the Colorectum
胰岛素抵抗和结直肠腺瘤
- 批准号:
6331928 - 财政年份:2001
- 资助金额:
$ 36.83万 - 项目类别:
Insulin Resistance and Adenomas of the Colorectum
胰岛素抵抗和结直肠腺瘤
- 批准号:
6514725 - 财政年份:2001
- 资助金额:
$ 36.83万 - 项目类别:
METHODS FOR EPIDEMIOLOGIC DATA WITH MISSING VALUES
具有缺失值的流行病学数据的方法
- 批准号:
2908021 - 财政年份:1999
- 资助金额:
$ 36.83万 - 项目类别:
METHODS FOR EPIDEMIOLOGIC DATA WITH MISSING VALUES
具有缺失值的流行病学数据的方法
- 批准号:
6633329 - 财政年份:1999
- 资助金额:
$ 36.83万 - 项目类别:
METHODS FOR EPIDEMIOLOGIC DATA WITH MISSING VALUES
具有缺失值的流行病学数据的方法
- 批准号:
6173743 - 财政年份:1999
- 资助金额:
$ 36.83万 - 项目类别:
METHODS FOR EPIDEMIOLOGIC DATA WITH MISSING VALUES
具有缺失值的流行病学数据的方法
- 批准号:
6376983 - 财政年份:1999
- 资助金额:
$ 36.83万 - 项目类别:
METHODS FOR EPIDEMIOLOGIC DATA WITH MISSING VALUES
具有缺失值的流行病学数据的方法
- 批准号:
6513439 - 财政年份:1999
- 资助金额:
$ 36.83万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 36.83万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 36.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 36.83万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 36.83万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




